Arlen PM - Search Results

1

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.

Gandhy SU, Karzai FH, Bilusic M, McMahon S, Cordes LM, Marte J, Weisman AJ, Perk TG, Lindenberg L, Mena E, Turkbey B, Arlen PM, Dahut WL, Figg WD, Choyke P, Gulley JL, Madan RA. Gandhy SU, et al. Among authors: arlen pm. Eur Urol Oncol. 2023 Oct 17:S2588-9311(23)00205-5. doi: 10.1016/j.euo.2023.09.010. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37858437

2

Optimizing the immune system to achieve control of the metastatic malignant lesion.

Arlen M, Arlen P. Arlen M, et al. J Cancer. 2013 Jun 28;4(5):427-32. doi: 10.7150/jca.6572. Print 2013. J Cancer. 2013. PMID: 23833687 Free PMC article.

3

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Terasawa H, et al. Clin Cancer Res. 2002 Jan;8(1):41-53. Clin Cancer Res. 2002. PMID: 11801539

4

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Among authors: arlen pm. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

5

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

6

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.

Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. Arlen PM, et al. J Immunol Methods. 2003 Aug;279(1-2):183-92. doi: 10.1016/s0022-1759(03)00185-6. J Immunol Methods. 2003. PMID: 12969559

7

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.

Arlen PM, Gulley JL, Tsang KY, Schlom J. Arlen PM, et al. Expert Rev Vaccines. 2003 Aug;2(4):483-93. doi: 10.1586/14760584.2.4.483. Expert Rev Vaccines. 2003. PMID: 14711334 Review.

8

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Clin Cancer Res. 2004 Mar 15;10(6):2139-49. doi: 10.1158/1078-0432.ccr-1011-03. Clin Cancer Res. 2004. PMID: 15041735

9

National Cancer Institute intramural approach to advanced prostate cancer.

Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. Arlen PM, et al. Clin Prostate Cancer. 2002 Dec;1(3):153-62. doi: 10.3816/cgc.2002.n.017. Clin Prostate Cancer. 2002. PMID: 15046690

10

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD. Tohnya TM, et al. Among authors: arlen pm. Clin Prostate Cancer. 2004 Mar;2(4):241-3. doi: 10.3816/cgc.2004.n.006. Clin Prostate Cancer. 2004. PMID: 15072608 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

111 results

Search Page